ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
TC BioPharm Holdings PLC

TC BioPharm Holdings PLC (TCBP)

0,5599
-0,0401
(-6,68%)
Fermé 01 Décembre 10:00PM
0,555
-0,0049
(-0,88%)
Après les heures de négociation: 10:48PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
0,5599
Prix Achat
0,543
Prix Vente
0,5559
Volume échangé
452 118
0,4359 Fourchette du Jour 0,57
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
0,60
Ouverture
0,54
Dernière Transaction
50
@
0.555
Dernière heure de transaction
Volume financier
US$ 241 719
VWAP
0,534637
Volume moyen (3 m)
-
Actions en circulation
582 020
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,06
Bénéfice par action (BPA)
-10,15
Chiffre d'affairess
-
Bénéfice net
-5,91M

À propos de TC BioPharm Holdings PLC

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Secteur
Coml Physical, Biologcl Resh
Industrie
Coml Physical, Biologcl Resh
Siège social
Scotland, Gbr
Fondé
-
TC BioPharm Holdings PLC est coté dans le secteur Coml Physical, Biologcl Resh de la NASDAQ avec le ticker TCBP. Le dernier cours de clôture d'TC BioPharm était de US$0,60. Au cours de la dernière année, les actions de TC BioPharm ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

TC BioPharm compte actuellement 582 020 actions en circulation. La capitalisation boursière d'TC BioPharm est de US$349 212,00 . TC BioPharm a un ratio cours/bénéfice (ratio PE) de -0.06.

TCBP Dernières nouvelles

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant PR Newswire EDINBURGH, Scotland, Nov. 12, 2024 EDINBURGH, Scotland, Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC...

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements PR Newswire EDINBURGH, Scotland, Oct. 30, 2024 EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm...

TCBP Responds to False Social Media Claim

TCBP Responds to False Social Media Claim PR Newswire EDINBURGH, Scotland, Oct. 25, 2024 TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the...

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic PR Newswire EDINBURGH, Scotland, Oct. 22, 2024 EDINBURGH, Scotland, Oct. 22, 2024 /PRNewswire/...

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening PR Newswire EDINBURGH, Scotland, Oct. 3, 2024 TC BioPharm Limited is partnering with...

TCBP Announces Site Opening of Guys and St. Thomas Hospital

TCBP Announces Site Opening of Guys and St. Thomas Hospital PR Newswire EDINBURGH, Scotland, Sept. 25, 2024 Additional London-based clinic to increase enrolment velocityLeading hospital with...

TCBP to Present at the 2024 ThinkEquity Conference in NYC

TCBP to Present at the 2024 ThinkEquity Conference in NYC PR Newswire EDINBURGH, Scotland, Sept. 24, 2024 EDINBURGH, Scotland, Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC...

/C O R R E C T I O N -- TC BioPharm/

/C O R R E C T I O N -- TC BioPharm/ PR Newswire EDINBURGH, Scotland, Sept. 12, 2024 In the news release, TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial...

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial PR Newswire EDINBURGH, Scotland, Sept. 12, 2024 No TCB008-related Adverse Events seen in any of the re-start...

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox PR Newswire EDINBURGH, Scotland, Sept. 9, 2024 EDINBURGH, Scotland, Sept. 9, 2024  /PRNewswire/ -- TC BioPharm...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BSLKBolt Projects Holdings Inc
US$ 0,71
(139,86%)
80,81M
PRZOParaZero Technologies Ltd
US$ 1,24
(94,14%)
205,02M
AIEVThunder Power Holdings Inc
US$ 0,47
(87,25%)
122,71M
PASGPassage Bio Inc
US$ 1,13
(69,52%)
15,44M
EPOWSunrise New Energy Company Ltd
US$ 1,06
(45,21%)
314,9k
APLTApplied Therapeutics Inc
US$ 2,03
(-76,31%)
43,9M
TGLTreasure Global Inc
US$ 0,2944
(-29,08%)
1,85M
PROCProcaps Group SA
US$ 1,51
(-27,75%)
106,08k
SHOTWSafety Shot Inc
US$ 0,104
(-20,00%)
1,43k
MONDMondee Holdings Inc
US$ 0,7102
(-19,59%)
297,63k
PRZOParaZero Technologies Ltd
US$ 1,24
(94,14%)
205,02M
NVDANVIDIA Corporation
US$ 138,25
(2,15%)
141,86M
AIEVThunder Power Holdings Inc
US$ 0,47
(87,25%)
122,71M
RGTIRigetti Computing Inc
US$ 3,05
(27,08%)
116,98M
MARAMARA Holdings Inc
US$ 27,42
(1,86%)
89,54M
Aucune Discussion Trouvée
Ajouter une Discussion